Hims & Hers Health, Inc. · NYSE:HIMS
Hims & Hers Health — Investor Presentation (August 2021)
17 slides from Hims & Hers Health's investor presentation, August 2021
Slide 1: Hims & Hers
Slide 2: Disclaimer
Disclaimer This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminolog
Slide 3: Business overview
business overview 3
Slide 4: The first digitally native, fully verticalized multi-condition health platform
the first digitally native, Consumer Brand fully verticalized multi-condition health Distributed Provider Network platform—providing access to high quality, Clinically Focused EMR integrated care from Digital Native Telehealth Platform start-to-finish... Digital Prescriptions Cloud Pharmacy 4
Slide 5: Rigorous, evidence-based guidelines and comprehensive provider training
all made possible by rigorous, evidence-based guidelines and comprehensive provider training 294 U.S. licensed providers Screening Board Certification Assessment Verification 94% average provider quality score We require all applicants to be Detailed credentials, licenses, and for reviewed encounter
Slide 6: This new paradigm of healthcare has unlocked unprecedented patient growth
this new paradigm of healthcare has unlocked unprecedented patient growth 3.9mm 3mm+ 16mm+ H&H telehealth Cumulative patient 2.8mm consultations since touchpoints1 launch 1.2mm 431k H&H telehealth consultations since launch ’18 ’19 ’20 Q2’21 Source: Company internal data Note: All numbers as of June
Slide 7: Adopted and championed by our Customers who represent the future of healthcare
adopted and championed by our Customer driven Customers who represent the organic growth our Customers are future of the healthcare system ambassadors for our brand, building community and driving organic growth 80% 70% Word of Mouth & User Generated Content of our Customers of US population is are
Slide 8: Our immediately addressable markets are massive and underpenetrated
our immediately addressable markets are massive and underpenetrated Erectile Anxiety & Hair Loss Dysfunction Depression Dermatology (“ED”) ~$3bn ~$4bn ~$14bn ~$44bn market size1 market size2 market size3 market size4 Note: Market size based on global spend 1. Grand View Research, 2020 2. Arizton, 20
Slide 9: Financials
EBT INS eg FO A a bid ee ig ene Ta
Slide 10: Attractive historical revenue growth and significant gross margin expansion
attractive historical revenue growth and significant gross margin expansion Year-over-Year Growth % % Gross Margin —— 209% 80% 29% 54% 74% Annual revenue $149 Annual gross profit $109 ($ millions) ($ millions) 136 CAGR % 275% CAGR $83 $45 $27 $8 2018A 2019A 2020A 2018A 2019A 2020A 10
Slide 11: Strong revenue growth since inception
strong revenue growth since inception $70 $61 Quarterly revenue ($ millions) $52 $41 $41 $36 $30 $25 $22 $20 $16 Q1’19 Q2’19 Q3’19 Q4’19 Q1’20 Q2’20 Q3’20 Q4’20 Q1’21 Q2’21 Q3’21E1 1. Q3'21 based on midpoint of $69M - $71M guidance range 11
Slide 12: Business summary
business summary (unaudited) Q4 ’19 Q1 ’20 Q2 ’20 Q3 ’20 Q4 ’20 Q1 ’21 Q2 ’21 Subscriptions (000s) 1 190 218 258 283 312 391 453 YoY Growth % 42% 39% 34% 45% 64% 79% 76% Net Orders (000s) 2 571 546 572 582 579 687 786 % Multi-Month Net Orders 5% 12% 17% 21% 25% 29% 30% AOV ($) 2 $43 $52 $58 $67 $69
Slide 13: Cumulative revenue per new subscriber by cohort
cumulative revenue per new subscriber by cohort 1,2 Month 1 Month 12 Month 24 Month 36 $450 $400 $363 +$91 $350 +$104 88% revenue retention3 $300 +$102 $250 $211 $200 M1 ’21 $1144 $191 $150 M1 ’20 $1104 $100 $50 2020 2019 2018 $0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Slide 14: Historical and projected financial summary
historical and projected financial summary ($ millions) 2018A 2019A 2020A 2021E Revenue $27 $83 $149 $251 - $255 YoY % Growth — 209% 80% 69% - 71% Gross Profit $8 $45 $109 — YoY % Growth — 472% 145% — % Margin 29% 54% 74% — Adjusted EBITDA1 ($68) ($66) ($8) ($35) - ($40) 1. This is a non-GAAP financ
Slide 15: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (as defined below), a non-GAAP financial measure. We use Adjusted EBITDA to evaluate our ongoing operations and for internal planning and forecasting purposes. We beli
Slide 16: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation ($ millions) 2018A 2019A 2020A Net Loss ($75) ($72) ($18) (+) Depreciation and Amortization $0 $0 $1 (+) Provision for Income Taxes $0 $0 $0 (-) Interest Income ($1) ($2) ($0) (+) Interest Expense $0 $0 $0 (+) Amortization of Debt Issuance Costs $0 $0 $0 (+) Stock-base
Slide 17: Slide 17
Hims & Hers Health — Investor Presentation (August 2021) on 6ix